DiaMedica Therapeutics Inc (DMAC) Stock Analysis

DiaMedica Therapeutics Inc (DMAC) is a publicly traded company in the HEALTHCARE sector. It trades at $5.77, carries a market capitalization of $314.68M. This page summarizes the public market data, fundamentals, and frequently asked questions for DMAC, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $5.77
• Market Cap: $314.68M
• EPS: $-0.71
• 52-Week High: $10.42
• 52-Week Low: $3.48

Market Sentiment

DiaMedica Therapeutics Inc currently has a Bullish sentiment score of 0.29.

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Minneapolis, Minnesota, specialized in developing innovative therapies for neurological and kidney diseases. The company's lead candidate, DM199, targets the enhancement of renal function in patients suffering from diabetic kidney disease, showcasing its commitment to addressing critical unmet medical needs. With a robust pipeline and a strong emphasis on clinical innovation, DiaMedica is strategically position...

GNG Research Analysis

GNG Research scores DiaMedica Therapeutics Inc (DMAC) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for DMAC.

Frequently Asked Questions

Does DMAC pay dividends?

DiaMedica Therapeutics Inc (DMAC) does not currently pay a regular dividend.

What is DMAC's market cap?

DiaMedica Therapeutics Inc (DMAC) has a market capitalization of $314.68M with a current stock price of $5.77.